Afatinib in Pretreated Patients With Advanced NSCLC Harbouring HER2 Exon 20 Mutations
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NICHE
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 03 Jan 2017 Status changed from recruiting to suspended.
- 17 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.